Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.49 |
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.46 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | RXRB | P28702 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15316160 | 0.85 | CA12 (0.48) | NPC1RAB9A | |
| SCHEMBL16237574 | 0.82 | TP53 (0.47) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13045999 | 0.82 | KMO (0.47) | LDHAKMONR1H4MAP2K4MAPK1 | |
| SCHEMBL19439104 | 0.82 | NR1H4 (0.50) | LDHAKMONR1H4MAP2K4MAPK1 | |
| SCHEMBL725997 | 0.81 | SLC7A5 (0.43) | LDHAMAP2K4 | |
| SCHEMBL31049680 | 0.81 | SLC7A5 (0.43) | LDHAMAP2K4 | |
| SCHEMBL27826923 | 0.80 | ALDH1A1 (0.48) | LDHAMAP2K4ADORA3ALDH1A1TSHR | |
| SCHEMBL19418814 | 0.80 | ADORA3 (0.52) | LDHAKMONR1H4MAP2K4MAPK1 | |
| SCHEMBL4052604 | 0.80 | ALOX5AP (0.49) | LDHAKMONR1H4MAP2K4MAPK1 | |
| SCHEMBL10066071 | 0.78 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135827-A1 | Substituted Tricyclics and Method of Use | ABBVIE SARL (LU) | 2019-05-09 | — | — | US | disclosed |
| EP-3322697-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | Abbvie S.a.r.l. (LU) | 2018-05-23 | — | — | EP | disclosed |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | ABBVIE S.Á.R.L. (LU) | 2018-02-08 | — | — | US | disclosed |
| US-9840513-B2 | Substituted tricyclics and method of use | ABBVIE S.Á.R.L. (LU) | 2017-12-12 | — | — | US | disclosed |
| US-20170015675-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-01-19 | — | — | US | disclosed |
| WO-2017009804-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-01-19 | — | — | WO | disclosed |
| EP-2555755-B1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIODIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF | VERTEX PHARMA (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2858645-A1 | PHARMACEUTICL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013185112-A1 | PHARMACEUTICL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-12 | — | — | WO | disclosed |
| CN-102933206-A | Solid forms of 3- (6- (1- (2, 2-difluorobenzo [ d ] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid | VERTEX PHARMA | 2013-02-13 | — | — | CN | disclosed |
| CN-102917692-A | Pharmaceutical compositions of 3- (6- (1- (2, 2-difluorobenzo [ D ] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid and methods of administration thereof | VERTEX PHARMA | 2013-02-06 | — | — | CN | disclosed |
| CN-102665715-A | Compositions for treatment of cystic fibrosis and other chronic diseases | VERTEX PHARMA | 2012-09-12 | — | — | CN | disclosed |
| US-8012999-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100227888-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-09 | — | — | US | disclosed |
| US-7754739-B2 | Modulators of CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080286204-A1 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227888-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | LDHA 3935/4885KMO 4738/4885NR1H4 84/4885 |
| US-20170015675-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | CFTR, F12, CHRM2 | LDHA 4620/4885KMO 1872/4885NR1H4 74/4885 |
| US-20080286204-A1 | MODULATORS OF CFTR | CFTR, ABCB1, ABCC4 | LDHA 3882/4885KMO 4706/4885NR1H4 101/4885 |
| US-20190135827-A1 | Substituted Tricyclics and Method of Use | CFTR, F12, CHRM2 | LDHA 4620/4885KMO 1872/4885NR1H4 74/4885 |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | CFTR, F12, CHRM2 | LDHA 4620/4885KMO 1872/4885NR1H4 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.